Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2B Clinical Trial for the Evaluation of Efficacy and Safety of RZL-012 in Subjects Having Dercum's Disease Lipomas

Next Previous
Trial Profile

A Double Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2B Clinical Trial for the Evaluation of Efficacy and Safety of RZL-012 in Subjects Having Dercum's Disease Lipomas

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RZL-012 (Primary)
  • Indications Adiposis dolorosa
  • Focus Registrational; Therapeutic Use
  • Sponsors Raziel Therapeutics

Most Recent Events

  • 23 Feb 2021 Status changed from not yet recruiting to completed.
  • 28 Jul 2020 Planned End Date changed from 30 Mar 2021 to 30 Jun 2021.
  • 28 Jul 2020 Planned primary completion date changed from 31 Jan 2021 to 30 Jun 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top